Saxenda
Saxenda is a daily injection given under the skin, typically in the abdomen. It is prescribed for chronic weight management in adults with obesity, or overweight with weight‑related conditions, alongside diet and exercise. Many people find it curbs appetite, helps them feel fuller sooner, and supports gradual, clinically supervised weight loss.
Saxenda 6mg / 6ml | 3 x 3ml | €349 | |
|---|---|---|---|
Saxenda 6mg / 6ml | 5 x 3ml | €519 |
What you need to know about Saxenda
Liraglutide, Saxenda, is a GLP‑1 receptor agonist that reduces appetite, slows gastric emptying, and helps regulate energy intake, supporting weight loss.
Long‑term weight management in eligible adults (and some adolescents) with obesity, alongside diet and physical activity, per UK criteria.
Once‑daily subcutaneous injection using a prefilled pen (abdomen, thigh, or upper arm), at approximately the same time each day. Rotate injection sites.
Titration: 0.6 mg daily for 1 week, then increase weekly to 1.2 mg, 1.8 mg, 2.4 mg, and 3.0 mg daily, as tolerated.
Nausea, vomiting, diarrhoea or constipation, abdominal pain, indigestion, headache, fatigue. Serious: pancreatitis, gallbladder disease, dehydration, rare allergic reactions.
If you drink, keep it moderate. Alcohol may worsen GI symptoms and can raise hypoglycaemia risk if combined with insulin or sulfonylureas.
Effective for weight loss, but on average produces less weight reduction than weekly semaglutide 2.4 mg or tirzepatide. Daily dosing may suit some; others prefer weekly injections.
GI intolerance, pancreatitis, gallstones, dehydration. Avoid in pregnancy and during breastfeeding. Not for type 1 diabetes or DKA.
Few direct interactions. Caution with insulin or sulfonylureas (risk of hypos—dose adjustments may be needed). It may slow gastric emptying and could affect absorption of some oral drugs.
Patient Information Leaflet, NHS weight management pages, and your prescriber or pharmacist.